Le Lézard
Classified in: Health
Subject: PET

Celebrate the New Year and Walk Your Dog Month in Style with YuMOVE


ORLANDO, Fla., Jan. 9, 2024 /PRNewswire/ -- Step into the pawsitive vibes of 2024 with YuMOVE, a high-quality joint supplement for dogs. As the American Kennel Club's official dog joint supplement, YuMOVE is wagging its tail in excitement to kick off the new year by urging dog owners to put their pets' mobility first. With January being the acclaimed National Walk Your Dog Month, it's the perfect time to embark on a journey of wellness for our furry companions.

The Dog Mobility & New Year Checklist

As the curtain rises on the new year, use YuMOVE's comprehensive checklist to ensure one's dog starts the year on the right foot:

If a dog exhibits any of these signs, consulting with a vet is recommended, as mobility concerns can affect dogs of all ages.

Embark on Healthier Walks in 2024
January signals the National Walk Your Dog Month ? the perfect time to dedicate to regular walks with furry companions. YuMOVE provides five tips to optimize the dog-walking experience:

Spread the Joy, Share Pet Tales on Social Media
As we usher in the new year, YuMOVE extends an invitation to all pet enthusiasts to share heartwarming stories on its vibrant social media platforms. Connect with YuMOVE on Instagram: @YuMOVE_USA or Facebook:  YuMOVE USA and join the collective celebration of the love and companionship pets bring into our lives. By participating, individuals stand a chance to win exclusive YuMOVE products as a token of appreciation.

Unlock the Power of YuMOVE
As the UK's #1 vet-recommended joint supplement brand1, YuMOVE is already supporting over two million dogs globally2 each year. With an unwavering commitment, YuMOVE delivers a high-quality dog joint supplement, scientifically proven to work in just six weeks.³ Rest easy with YuMOVE's 6-Week Money-Back Guarantee4, ensuring satisfaction or your money back.

Embrace the Transformation
For first-time subscription purchases, YuMOVE is pleased to offer a 15% discount on any YuMOVE hip and joint supplement for dogs using the code "PRESS15."

Discover More:  YuMOVE.
Customer Reviews:  Trustpilot.
Watch YuMOVE's Latest Commercial:  YuMOVE: We're Obsessed with Dogs.

Footnotes

1YuMOVE is the UK's no.1 vet recommended joint supplement brand with 8 out of 10 UK veterinarians recommending YuMOVE Advanced 360 ? Survey conducted by CM Research. November 2021 (n = 101).
2
YuMOVE brand tracking study 2023.
3YuMOVE Joint Care is scientifically proven to work in 6 weeks by an in vivo, double blind, placebo-controlled, objectively measured canine clinical study by the Royal Veterinary College, UK (excluding YuMOVE for Young Dogs.)
4
For full terms/conditions see yumove.com/guarantee.

Media Contact
Phillip Sontag
917-446-4123
370894@email4pr.com

SOURCE YuMOVE


These press releases may also interest you

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. The...

at 00:00
Author Kory L. Wilson and his family have experienced the benefits of information he shares in Home Remedies: A Guidebook To Breaking Away From Big Pharma ($15.99, paperback, 9781662896668; $6.99, e-book, 9781662896675). For years, I have collected...

15 mai 2024
Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates.Q4 2023 gross profit margin1 of 39.7% was relatively flat compared to Q3...

15 mai 2024
On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and...

15 mai 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...

15 mai 2024
Bristol Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment...



News published on and distributed by: